Axsome shares jump as settlement will keep Teva's Auvelity generic off the market until 2038
Shares of Axsome Therapeutics jumped by more than 20% after the company resolved a patent infringement lawsuit against Teva Pharmaceuticals. The settlement will keep Teva's generic version of Axsome's major depressive disorder drug Auvelity off the market until at least 2038.
Shares of Axsome Therapeutics jumped by more than 20% after the company resolved a patent infringement lawsuit against Teva Pharmaceuticals. The settlement will keep Teva's generic version of Axsome's major depressive disorder drug Auvelity off the market until at least 2038.
